Please read and agree to the
terms and conditions
of this site.
I agree
Medical Technology
/tech
Clear filters and search
Format
photo
Tags
biotech
boston blog main
clinical trials
life sciences
national blog main
boston
boston top stories
fda
san francisco blog main
dyne therapeutics
myotonic dystrophy type 1
rare disease drugs
san diego blog main
akouos
astellas pharma
astellas pharmaceuticals
atlas venture
audentes therapeutics
avidity biosciences
biotech ipos
black diamond therapeutics
bladder cancer
bluebird bio
blueprint medicines
california institute for biomedical research
cancer
cancer drugs
deals
decibel therapeutics
deciphera pharmaceuticals
duchenne muscular dystrophy
eli lilly
endometral cancer
europe blog main
european society for medical oncology
facioscapulohumeral muscular dystrophy
frequency therapeutics
gene therapy
glioblastoma
harvard university
What
drug
4
×
ipo
4
×
medicines
therapeutics
4
×
developing
dyne
genetic
muscle
rare
affects
ago
americans
approved
biotech
biotechs
black
brings
cancer
clinic
companies
company
considering
data
date
diamond
diseases
disorders
dyne’s
early
eluded
expected
experimental
eyes
fda
frequency
having
hearing
hopes
humans
ipos
Language
unset
Current search:
ipo
×
therapeutics
×
drug
×
@xconomy.com
3 years ago
Dyne’s Upsized IPO Brings In $233M for Muscle Disorders Drug R&D
@xconomy.com
3 years ago
Dyne Eyes IPO for R&D of Genetic Medicines for Rare Muscle Diseases
@xconomy.com
4 years ago
Black Diamond Lines Up IPO as Lead Cancer Drug Nears Clinic
@xconomy.com
4 years ago
Frequency Plans IPO for Hearing Loss Drug & More Regenerative Meds
